Khadke Suresh, Gupte Poonam, Mourya Akanksha, Yadav Amit, Mane Sarika, Joshi Asavari, Mahajan Madhavi, Mishra Manisha, Bhalerao Supriya
Interactive Research School for Health Affairs, Bharati Vidyapeeth (Deemed to be University), Pune, India.
Department of Kayachikitsa, College of Ayurveda, Bharati Vidyapeeth (Deemed to be University), Pune, India.
Perspect Clin Res. 2023 Jul-Sep;14(3):130-138. doi: 10.4103/picr.picr_100_22. Epub 2023 May 22.
Clinical study for immunity.
The present study aimed to assess the effect of proprietary polyherbal formulation (PPHF), labelled as Kofol immunity tablets (KIT) on innate and adaptive immune responses in healthy individuals, on the backdrop of COVID-19 pandemic.
Single-blind, randomized, placebo-controlled, exploratory study in institutional setting.
Post Ethics Committee permission, screened healthy individuals of either sex aged 18-35 years were randomized to PPHF/Placebo for 2 months. Major assessment variables included peak expiratory flow rate (PEFR), questionnaire-based immune status, perceived stress, and quality of life (QOL) with immune-specific cell counts (CD4+, CD8+), cytokines (interferon gamma [IFN-γ], tumor necrosis factor-alpha [TNF-α], interleukin 10 [IL-10]), and oxidative stress in red blood cells (RBCs) (malondialdehyde (MDA), glutathione peroxidase [GPx]), done at day 60.
Mean ± standard deviation and paired/unpaired test for parametric data analysis while median (range) and Wilcoxon Rank sum test/Mann-Whitney test for nonparametric data analysis, were done. Categorical data was analyzed using Chi-square test. GraphPad InStat software, version 9 was used with < 0.05, as the level of statistical significance.
Of 52 recruited, 28 individuals completed the study. PPHF significantly increased PEFR, improved immune status along with QOL compared to baseline. It also decreased perceived stress from moderate and severe grade to mild. Serum IFN-γ levels remained almost constant post-PPHF treatment. PPHF significantly decreased MDA and increased GPx in RBCs. Significant decrease and increase in TNF-α and IL-10, respectively, were seen in PPHF group. The safety parameters post-PPHF treatment remained within normal reference ranges.
PPHF is an efficacious and safe formulation with immunomodulatory potential.
免疫相关临床研究。
本研究旨在评估在新冠疫情背景下,标记为Kofol免疫片(KIT)的专利复方草药制剂(PPHF)对健康个体先天性和适应性免疫反应的影响。
在机构环境中进行的单盲、随机、安慰剂对照探索性研究。
经伦理委员会批准后,筛选年龄在18 - 35岁的健康男女个体,随机给予PPHF/安慰剂,为期2个月。主要评估变量包括呼气峰值流速(PEFR)、基于问卷的免疫状态、感知压力和生活质量(QOL),同时检测免疫特异性细胞计数(CD4 +、CD8 +)、细胞因子(干扰素γ [IFN - γ]、肿瘤坏死因子α [TNF - α]、白细胞介素10 [IL - 10])以及红细胞(RBC)中的氧化应激(丙二醛[MDA]、谷胱甘肽过氧化物酶[GPx]),检测在第60天进行。
对于参数数据分析,采用均值±标准差以及配对/非配对检验;对于非参数数据分析,采用中位数(范围)以及Wilcoxon秩和检验/Mann - Whitney检验。分类数据采用卡方检验进行分析。使用GraphPad InStat软件9版,以P < 0.05作为统计学显著性水平。
招募的52名受试者中,28人完成了研究。与基线相比,PPHF显著提高了PEFR,改善了免疫状态和生活质量。它还将感知压力从中度和重度降至轻度。PPHF治疗后血清IFN - γ水平几乎保持不变。PPHF显著降低了红细胞中的MDA并提高了GPx。PPHF组中TNF - α显著降低,IL - 10显著升高。PPHF治疗后的安全参数保持在正常参考范围内。
PPHF是一种具有免疫调节潜力的有效且安全的制剂。